Overview

Heparin or Enoxaparin in Patients With Cancer

Status:
Completed
Trial end date:
1999-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor. PURPOSE: Randomized clinical trial to compare the effectiveness of heparin with that of enoxaparin in patients who have cancer.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Calcium heparin
Enoxaparin
Heparin
Criteria
DISEASE CHARACTERISTICS: Histologically proven malignancy, including lymphomas No leukemias

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
expectancy: Greater than 6 months Hematopoietic: Hemoglobin greater than 8.5 g/dL Platelet
count greater than 100,000/mm3 No history of heparin and/or low weight molecular heparin
induced thrombocytopenia No history of bleeding diathesis Hepatic: No history of
coagulation factor deficiency No hepatic encephalopathy No hepatic failure No cirrhosis No
hemophilia Renal: Creatinine less than 2.5 mg/dL (no greater than upper limit of normal for
diabetes mellitus) Cardiovascular: No New York Heart Association class III or IV heart
disease No congestive heart failure No uncontrolled hypertension (i.e., systolic blood
pressure at least 180 mmHg and diastolic blood pressure at least 110 mmHg) No endocarditis
No hemorrhagic stroke No prior or concurrent deep vein thrombosis Pulmonary: No prior or
concurrent pulmonary embolus Other: No known allergy to enoxaparin or standard heparin No
known allergy to fish (e.g., protamine sulfate) or swine products No active ulcerative
disease or angiodysplasia of the gastrointestinal (GI) tract or active GI bleeding within
the past 6 months No other active significant medical illness or major failure of any organ
system No refusal of donor blood products secondary to religious or other reasons Not
pregnant or nursing

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Concurrent
chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:
At least 1 month since prior eye, spinal cord, or CNS surgery Other: At least 1 day since
prior heparin or enoxaparin At least 1 week since prior therapeutic coumadin (prior
prophylactic coumadin allowed) No other concurrent anticoagulants